Table 1.

Baseline characteristics of 50,673 patients stratified by serum triglyceride/HDL cholesterol ratio deciles

Serum Triglyceride/HDL Cholesterol Ratio
Characteristics<1.591.59–<2.092.09–<2.572.57–<3.073.07–<3.643.64–<4.304.30–<5.185.18–<6.416.41–<8.63≥8.63
(n=5067)(n=5072)(n=5062)(n=5062)(n=5072)(n=5071)(n=5061)(n=5068)(n=5070)(n=5068)
Age, yr63.9±15.564.4±15.464.1±15.264.1±14.763.9±14.963.0±14.762.8±14.562.1±14.261.1±14.359.2±14.1
Sex, % women46.747.345.246.943.943.742.642.639.938.0
Race, %
 White35.441.143.343.946.248.449.950.052.055.3
 Black48.140.137.835.132.230.127.226.122.218.5
 Hispanic10.612.513.014.415.115.216.217.219.219.3
 Asian2.63.02.82.92.93.02.93.43.23.2
 Others3.13.43.13.83.73.33.83.33.53.6
Primary insurance, %
 Medicare54.855.055.055.054.853.552.952.050.849.8
 Medicaid6.56.16.45.56.76.36.56.56.86.9
 Others38.838.938.639.538.540.240.641.442.443.3
Initial vascular access type, %
 Central venous catheter70.772.472.474.174.874.475.375.676.876.4
 Arteriovenous fistula17.516.816.714.814.616.115.415.414.314.7
 Arteriovenous graft5.34.74.95.34.34.14.03.53.43.3
 Others and unknown6.56.16.05.86.35.45.35.55.55.6
Comorbidities, %
 Diabetes60.560.661.561.962.562.164.063.664.966.3
 Hypertension56.855.052.352.552.951.150.649.949.247.3
 Congestive heart failure37.736.536.436.635.937.336.335.936.037.5
 Atherosclerotic heart disease17.618.119.018.018.319.317.918.018.218.2
 Other cardiovascular disease17.316.316.816.717.116.916.216.217.016.7
 Cerebrovascular disease1.91.31.81.61.81.91.71.42.11.9
 Dyslipidemia35.433.935.033.234.334.735.233.934.836.4
 HIV0.40.30.30.40.40.40.60.40.70.8
 COPD5.45.35.15.25.65.15.54.55.14.5
 History of malignancy2.02.12.12.62.32.22.22.32.52.5
Alcohol dependence, %0.40.30.30.30.20.20.30.30.30.1
Substance abuse, %0.50.40.40.20.20.20.20.20.20.2
Statin therapy, %37.040.139.241.241.941.642.942.642.842.8
Dialysis dose: single pool Kt/V1.5±0.31.5±0.31.5±0.31.5±0.31.5±0.31.5±0.31.5±0.31.5±0.31.5±0.31.4±0.3
Body mass index, kg/m225.9±6.526.7±7.227.2±7.127.8±7.327.9±7.328.5±7.429.0±7.529.4±7.429.8±7.530.6±7.4
Lipid parameters
 Total cholesterol, mg/dl151.9±41.5146.5±40.9145.1±41.7146.4±42.7145.9±42.5148.3±43.6149.8±44.7152.5±43.7157.6±46.5168.0±55.5
 LDL-C, mg/dl78.4±31.978.3±31.978.1±33.080.0±34.279.9±34.181.0±35.381.5±36.881.4±36.381.9±38.378.4±42.2
 TG, mg/dl73.2±18.691.8±22.1106.2±24.9119.7±28.1132.7±30.8148.6±34.7165.9±38.1190.3±42.7225.5±52.1310.4±91.7
 HDL-C, mg/dl59.0±14.549.9±11.945.7±10.742.6±9.939.7±9.237.6±8.735.2±8.033.1±7.430.6±6.927.0±6.8
 TG/HDL-C ratio1.3±0.21.8±0.12.3±0.12.8±0.13.3±0.24.0±0.24.7±0.25.8±0.47.4±0.611.7±2.6
Other laboratory parameters
 Hemoglobin, g/dl11.1±1.211.1±1.211.1±1.211.1±1.211.1±1.211.1±1.211.1±1.211.1±1.211.1±1.211.1±1.2
 White blood cells, ×103/µl7.2±2.37.4±2.47.6±2.47.7±2.77.8±2.47.8±2.57.9±2.58.1±2.88.1±2.88.2±3.0
 Albumin, g/dl3.5±0.53.5±0.53.5±0.53.5±0.53.5±0.53.5±0.53.5±0.53.5±0.53.5±0.53.6±0.5
 Calcium, mg/dl9.1±0.69.1±0.59.1±0.69.1±0.69.1±0.69.1±0.69.1±0.69.1±0.59.1±0.69.1±0.6
 Phosphorus, mg/dl4.9±1.14.9±1.14.9±1.14.9±1.14.9±1.24.9±1.14.9±1.14.9±1.14.9±1.15.0±1.2
 Intact PTH, pg/ml330317317313313315312316314312
(202–516)(201–499)(198–486)(199–479)(196–488)(201–478)(198–481)(196–486)(196–474)(196–474)
 Bicarbonate, mEq/L23.9±2.824.0±2.823.8±2.723.8±2.723.8±2.723.7±2.723.6±2.723.5±2.623.3±2.623.0±2.6
 TIBC, mg/dl224.6±45.4223.4±46.1222.3±46.8222.4±47.6223.2±47.8223.9±49.1226.0±48.7226.8±48.7229.1±50.0234.8±52.7
 Ferritin, ng/ml253260249280283293296304316312
(146–429)(154–438)(163–465)(168–482)(170–469)(171–508)(174–496)(184–506)(185–535)(182–535)
  • Data are presented as means±SD, median (interquartile range), or percentage. COPD, chronic obstructive pulmonary disease; LDL-C, LDL cholesterol; TG, triglyceride; HDL-C, HDL cholesterol; TG/HDL-C, triglyceride/HDL cholesterol ratio; PTH, parathyroid hormone; TIBC, total iron binding capacity.